News | Breast Density | January 15, 2016

Volpara Solutions Receives FDA Clearance for Volpara Density Maps

Complement for VolparaDensity software presents 3-D quantitative volumetric information in a 2-D image to display true breast density, size

Volpara, Density Maps, breast density measurement, FDA clearance

January 15, 2016 — Volpara Solutions announced that it has received a new 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Volpara Density Maps. The new solution is designed to help radiologists address the requirement in the Breast Imaging Reporting and Data System (BI-RADS) 5th Edition Atlas to provide “an overall assessment of the volume of attenuating tissues in the breast, to help indicate the relative possibility that a lesion could be obscured.”

Volpara Density Maps present the 3-D quantitative volumetric information created by the VolparaDensity algorithm in a 2-D image that is available as an additional DICOM secondary capture image. Going beyond the measurement of the area of dense fibroglandular tissue, VolparaDensity measures the compressed thickness and volume of dense tissue, which enables the software to highlight specific parts of the breast tissue that are especially dense, including marking the densest 1-2 cm region of the image that might warrant closer inspection due to the masking risk.

VolparaDensity results have been clinically validated in independent studies to correlate to mammography sensitivity. Results of the study “Quantifying the Potential Masking Risk of Breast Density in Mammographic Screening,” conducted by researchers from Elizabeth Wende Breast Care (EWBC), demonstrated that VolparaDensity captures the potential masking risk of breast density more precisely compared to the widely used BI-RADS density categories. Additionally, several studies using Volpara Density Maps presented at the Radiological Society of North America (RSNA) 2015 annual meeting indicate promise for identifying those women at risk of a masked cancer. In the study, “How Can We Identify Women at Risk for a Masked Cancer, Who May Benefit from Supplemental Screening?,” researchers from Nijmegen used novel masking measures derived from density maps to help identify women at risk of a masked cancer.

Beyond masking risk, “For Presentation” images used for cancer detection are often displayed zoomed in, with heavy image processing, making it difficult to judge breast density, especially density changes over time. Volpara Density Maps are designed to show true breast density at true size, providing a standardized means of visually assessing which regions of dense tissue change over time.

Volpara recently announced another 510(k) clearance from the FDA for VolparaDensity covering VolparaDensity version 3.1, which has been specifically designed to correlate to the Fifth Edition of the BI-RADS Atlas from the American College of Radiology (ACR). VolparaDensity v3.1 is the first density assessment tool available clinically for use with digital breast tomosynthesis data sets from Hologic, GE and Siemens tomosynthesis systems, according to Volpara.

For more information: www.volparasolutions.com

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...